| Year | Q2 2024 | Q1 2024 |
|---|---|---|
| Total Revenue | 6.42B | 5.91B |
| Cost of Revenue | 2.58B | 3.63B |
| Gross Profit | 3.84B | 2.28B |
| Operating Expenses | 3.84B | 1.2B |
| Research and Development | 0 | 0 |
| Selling, General & Administrative Expenses | 0 | 1.2B |
| Selling & Marketing Expenses | 0 | 0 |
| General & Administrative Expenses | 0 | 0 |
| Other Expenses | 3.84B | 0 |
| Operating Income | 1.16B | 1.08B |
| Total Other Income/Expenses Net | 84.25M | 120.25M |
| Income Before Tax | 1.25B | 1.2B |
| Income Tax | 268.37M | 309.51M |
| Net Income | 967.16M | 887.52M |
| Basic EPS | 2.13 | 1.96 |
| EPS Diluted | 2.13 | 1.96 |
| Basic Average Shares | 454.07M | 452.82M |
| Diluted Average Shares | 454.07M | 452.82M |
| EBITDA | 1.47B | 1.43B |
Marksans Pharma Limited
MARKSANS.NS
NSE
205.58INR11.43 (6.52%)
MARKSANS.NS Financial Statements
Retained Earning Schedule
| Year |
|---|
| Retained Earnings (Previous Year) |
| Net Income |
| Stock Repurchases |
| Dividend Paid |
| Retained Earnings |
| Other Distributions |
PPE Schedule
| Year |
|---|
| Gross PPE |
| Annual Depreciation |
| Capital Expenditure |
| Net PPE |
Intangible and Goodwill Schedule
| Year |
|---|
| Acquisitions and Adjustments |
| Goodwill (Previous Year) |
| Goodwill |